Think of Nesina as a "Me Too" Similar to Januvia, Onglyza, and Trajenta

January 2015

Nesina (nes-SEE-na, alogliptin) will compete in a crowded market of "gliptins" for treating type 2 diabetes.

Nesina is the latest "me too" diabetes drug to hit the market.

Think of it as another Januvia (sitagliptin), Onglyza (saxagliptin), or Trajenta (linagliptin).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Vaccines Vaccine errors are on the rise
Diabetes Meds Think of Nesina as a "Me Too" Similar to Januvia, Onglyza, and Trajenta
Med Administration Be Aware Tipping the Head Forward can Make Pill Swallowing Easier
Cholesterol more Rxs for ezetimibe (Ezetrol, etc) for lowering cholesterol
Antidepressants Don't Be Surprised to See High Co-Pays or Insurance Rejects With Trintellix
Chemotherapy Apply a "Cytotoxic" Auxiliary Label to Oral Chemo Rxs
Interactions Alert Pharmacists of Interactions with TMP/SMX and BP Meds
Pregnancy & Nursing Expect Pregnant Women to use Enoxaparin for At Least Three Months After a Clot
Eye Health how to manage dry eyes
Bipolar Disorder Look for Patients Who are Late or Not Refilling Their Bipolar Meds
Needles & Syringes Feel Comfortable Dispensing the Highest Gauge Insulin Syringe Needle Available